Core Insights - DBV Technologies will participate in the ACAAI 2025 Annual Scientific Meeting from November 6 to 10 in Orlando, Florida [1] - The company will host a Product Theater discussing the benefits of early intervention in food allergy management [2][3] - A planned Phase 2 clinical study will assess the efficacy and safety of the VIASKIN® Peanut patch for peanut-allergic infants aged 6 to 12 months [2][4] Product Theater Details - Dr. Gideon Lack will lead discussions on proactive food allergy management and the potential of the VIASKIN® Peanut patch [3] - The study aims to determine if earlier intervention can facilitate ad lib peanut consumption in young children [3] - Dr. Matthew Greenhawt will present end-of-study results from the EPITOPE study during the meeting [3][8] Company Commitment - DBV Technologies emphasizes its commitment to the younger patient population in the food allergy community [4] - The company anticipates a potential BLA filing for the VIASKIN® Peanut patch for toddlers aged 1 to 3 years in the second half of next year [4] - DBV is focused on developing treatment options for food allergies using its proprietary VIASKIN® patch technology [9] Event Participation - DBV will exhibit at booth 711 and sponsor the 34th Annual FIT Bowl™, a competition testing knowledge in allergy, asthma, and immunology [6] - The competition is scheduled for November 8, 2025 [6] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, with operations in North America [10] - The company is dedicated to transforming the care of individuals with food allergies through innovative therapies [9]

Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 - continuing Idorsia’s trajectory towards profitabilityAprocitentan (TRYVIO/JERAYGO) the first and only dual ERA indicated for systemic hypertension and the only new medicine to be included in the ACC/AHA Hypertension Management guidelinesOperating cash runway extended beyond profitability into 2028 following CHF 65.6 million financing ...

Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 – continuing Idorsia’s trajectory towards profitabilityAprocitentan (TRYVIO/JERAYGO) the first and only dual ERA indicated for systemic hypertension and the only new medicine to be included in the ACC/AHA Hypertension Management guidelinesOperating cash runway extended beyond profitability into 2028 following CHF 65.6 million financing ...

Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of 89bio, Inc. (“89bio”, NASDAQ: ETNB) at a price of $14.50 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain milestone payments of up to an aggregate of $6.00 per share in cash ...

Core Insights - InnoCare Pharma announced promising data for its next-generation pan-TRK inhibitor zurletrectinib (ICP-723) aimed at treating pediatric and adolescent patients with advanced solid tumors [1][3] Group 1: Clinical Trial Results - The phase I/II clinical trial results were presented at the Congress of International Society of Paediatric Oncology (SIOP) 2025, highlighting the safety, pharmacokinetics, and efficacy of zurletrectinib [2] - Zurletrectinib showed a favorable safety profile and promising antitumor activity in patients with NTRK/ROS1-altered solid tumors, indicating its potential as a next-generation therapy [3] - The predominant tumor types included NTRK-rearranged spindle cell tumors and primary central nervous system tumors [4] Group 2: Dosage and Efficacy - The Recommended Phase 2 Dose (RP2D) was established at 7.2 mg/m² for pediatric patients and 8 mg for adolescents, with pharmacokinetic profiles showing comparable exposure levels between pediatric/adolescent and adult patients [4] - As of July 31, 2025, the objective response rate (ORR) was reported at 90% in NTRK fusion patients, with all patients resistant to first-generation TRK inhibitors achieving partial responses [5] - No dose-limiting toxicities were observed, and treatment-related adverse events were predominantly grade 1-2, further supporting the favorable safety profile of zurletrectinib [5] Group 3: Company Overview - InnoCare is a commercial stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class and/or best-in-class drugs for cancer and autoimmune diseases with unmet medical needs [6] - The company has established branches in major cities including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [6]

Core Viewpoint - Mind Medicine (MindMed) Inc. has announced the pricing of an underwritten public offering of 18,375,000 common shares at a price of $12.25 per share, aiming to raise significant capital for its operations [1]. Group 1 - The public offering consists of 18,375,000 common shares without par value [1]. - The offering price is set at $12.25 per common share [1]. - The gross proceeds from the offering, before deducting underwriting discounts and commissions, will be substantial [1].

Core Viewpoint - Savara Inc. has announced the pricing of a public offering of common stock and pre-funded warrants, indicating a strategic move to raise capital for its operations focused on rare respiratory diseases [1] Group 1: Offering Details - The company is offering 23,809,524 shares of its common stock at a price of $4.20 per share [1] - Additionally, the offering includes pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per warrant [1] - The pricing is set before deducting underwriting discounts and commissions, highlighting the financial structure of the offering [1]

Core Viewpoint - Quantum BioPharma Ltd. is conducting a non-brokered private placement of up to 30 Class A Multiple Voting Shares at a price of $25 per share, aiming for gross proceeds of up to $750 million, primarily to enhance voting rights and for general working capital purposes [1][2]. Group 1: Offering Details - The private placement is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz, existing holders of Class A Multiple Voting Shares [1][3]. - If fully subscribed, the voting rights attached to Class A Multiple Voting Shares will increase to 75.27%, nearly restoring the percentage to that at the time of the company's IPO in 2018 [2]. - The board of directors unanimously approved the Offering, excluding Saeed and Durkacz from discussions due to their interests [2]. Group 2: Related Party Transactions - The Offering involves related-party transactions as it is anticipated that Xorax Family Trust and Fortius Research and Trading Corp. will purchase all Class A Multiple Voting Shares issued [3]. - The transaction is expected to be exempt from formal valuation and minority shareholder approval requirements under MI 61-101, as the fair market value will not exceed 25% of the company's market capitalization [3]. Group 3: Shareholder Structure - Prior to a recent transfer, the Transferor and Joint Actors held approximately 50% of the outstanding Class A Multiple Voting Shares and 24.85% of the voting rights attached to all voting securities [7]. - Following the transfer of 77,000 Class B Subordinate Voting Shares, the ownership structure changed, with the Transferor and Joint Actors now holding approximately 23.77% of the voting rights [8]. Group 4: Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at treating multiple sclerosis [12]. - The company retains a 20.10% ownership in Unbuzzd Wellness Inc., which includes a royalty agreement for sales from its product unbuzzd™ [12].

Core Viewpoint - Ascentage Pharma Group International is actively participating in investor conferences in November 2025, highlighting its ongoing commitment to engage with the investment community and showcase its innovative biopharmaceutical pipeline [1][7]. Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [2][5]. - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors [2]. Product Pipeline - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for chronic myelogenous leukemia (CML) patients with specific mutations and is included in the China National Reimbursement Drug List [3]. - Olverembatinib is currently undergoing registrational Phase III trials, including POLARIS-2 for CML and POLARIS-1 and POLARIS-3 for other leukemia types [3]. - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for hematologic malignancies, with multiple global registrational Phase III trials ongoing [4]. Collaborations and Partnerships - Ascentage Pharma has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer [5]. - The company collaborates with prominent research institutions such as Dana-Farber Cancer Institute and Mayo Clinic to enhance its research and development capabilities [5].

Core Viewpoint - Ascentage Pharma Group International is actively participating in investor conferences in November 2025, highlighting its ongoing commitment to engage with the investment community and showcase its innovative biopharmaceutical pipeline [1][7]. Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [2][5]. - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors [2]. Product Pipeline - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for chronic myelogenous leukemia (CML) patients with specific mutations and is included in the China National Reimbursement Drug List [3]. - Olverembatinib is currently undergoing registrational Phase III trials for CML and other leukemia types [3]. - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for hematologic malignancies, with multiple global registrational Phase III trials ongoing [4]. Research and Development - Ascentage Pharma has established a robust R&D capability and holds a portfolio of global intellectual property rights [5]. - The company has formed partnerships with leading biotechnology and pharmaceutical companies, enhancing its research and development efforts [5].